1. Scrip
  2. >>Business

While Amgen Sees Success For Two Growth Drivers, Headwinds Remain

Breakthrough Drugs Sotorasib, Tezepelumab Edge Closer To Market

 
• By Mandy Jackson

Scrip discussed key wins for sotorasib in lung cancer and tezepelumab in asthma with Amgen executives Murdo Gordon and David Reese, but COVID-19 and other challenges are looming.

Amgen sign at biopharmaceutical company campus in Silicon Valley, biotech company headquartered in Thousand Oaks - South San Francisco, CA, USA - 2020
Amgen's sotorasib is filed with the US FDA; tezepelumab is being prepared for filings • Source: Shutterstock

Amgen, Inc. entered 2021 with two new high-profile potential additions to its commercial portfolio – sotorasib for non-small cell lung cancer patients with KRAS G12C mutations and tezepelumab for severe asthma. But while Amgen executive vice presidents David Reese and Murdo Gordon are looking forward to bringing these therapies to market in the next year or so, COVID-19 impacts on sales and competitive pressures remain near-term headwinds to the company’s growth.

Scrip spoke with Reese, EVP of research and development, and Gordon, EVP of global commercial operations, about pivotal data, filing...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Business

Finance Watch: Did Mid-Summer Usher In A Mega-Round Comeback?

 
• By Mandy Jackson

Private Company Edition: Hatteras Venture Partners now has more than $900m under management. Also, in recent $100m-plus VC rounds, Strand Therapeutics raised a $153m series A, ARTBIO revealed a $132m series B and Minghui Pharmaceutical secured a $131m pre-IPO round.

Tonix Ready To Revive Fibromyalgia Market With Tonyma

 
• By Joseph Haas

The first new drug for fibromyalgia since 2009, Tonyma is a reformulation of cyclobenzaprine intended for chronic therapy. Tonix said the drug targets non-restorative sleep.

Incretin Revolution: Obesity And Diabetes Drugs Redefine Pharma’s Sales Leaders

 
• By Edwin Elmhirst

By 2030, the pharmaceutical company leaderboard will be transformed as incretin-based therapies propel Eli Lilly and Novo Nordisk to the top, while companies reliant on aging blockbuster drugs see their dominance wane.

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By Vibha Ravi

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

More from Scrip

Executives On The Move: Instylla And Geron Get New CEOs

Recent moves in the industry include changes at the top at Meitheal Pharmaceuticals, Ardelyx and AIRNA, plus five companies get new CMOs.

Zydus Looks To Ride gIbrance Exclusivity Wave; GLP-1 Battle-Ready With Differentiated Pen

 
• By Vibha Ravi

Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.

Sarepta Sells Arrowhead Shares To Raise Cash, Pay Arrowhead

 
• By Mandy Jackson

Sarepta is in a cash crunch with sales of Elevidys slumping due to safety concerns and with financial commitments coming due, including debt repayments and milestone fees for its partner Arrowhead.